Mainstay mulls funding options as it prepares for US expansion

Medical Mainstay in the US: Has received approval for a clinical trial. Product described as a ‘pacemaker for back pain’

1st November, 2015
Peter Crosby, chief executive of Mainstay Medical Picture: Feargal Ward

Mainstay Medical, the publicly listed Irish medtech company, is set to push the button on a US expansion as it awaits clearance for its back-pain device in Europe.

The company has received approval for a US clinical trial of its device, which has been described as a ‘pacemaker for back pain’, and is negotiating contracts with test sites in America.

Listed in Dublin and on Paris’ Euronext stock exchange, Mainstay is likely to...

Subscribe from just €1 for the first month!


What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

The twelve deals of the year

Alphabet soup: 2021 in review

EY reports €393m revenues in Republic of Ireland for 2021 financial year